This post was originally published on this site
The site with about 246 employees specialises in producing pharmaceutical oral solid dosage products for distribution mostly in U.S. and Canadian markets.
It said the decision to close the site had come before it announced a strategic review of Sandoz, which it plans to spin off to sharpen the group’s focus on patented prescription medicines.
